Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N’-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily
出版年份 2015 全文链接
标题
Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N’-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily
作者
关键词
-
出版物
Scientific Reports
Volume 5, Issue 1, Pages -
出版商
Springer Nature
发表日期
2015-11-16
DOI
10.1038/srep16750
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
- (2014) Zheng Zhao et al. ACS Chemical Biology
- Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
- (2014) Mohammad Hojjat-Farsangi INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery of Biarylaminoquinazolines as Novel Tubulin Polymerization Inhibitors
- (2014) Giovanni Marzaro et al. JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis and Evaluation of Phosphorus Containing, Specific CDK9/CycT1 Inhibitors
- (2014) Gábor Németh et al. JOURNAL OF MEDICINAL CHEMISTRY
- Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy
- (2014) Alexander A Warkentin et al. eLife
- Quinazoline-based multi-tyrosine kinase inhibitors: Synthesis, modeling, antitumor and antiangiogenic properties
- (2013) Maria Teresa Conconi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
- (2013) Kerstin Maria Kampa-Schittenhelm et al. Molecular Cancer
- Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase
- (2013) L. Sutto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor
- (2013) C. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sulfur-containing amino acids in 7TMRs: molecular gears for pharmacology and function
- (2013) Arnau Cordomí et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
- (2012) Vandana Lamba et al. CURRENT PHARMACEUTICAL DESIGN
- Quinazoline derivatives as potential anticancer agents: a patent review (2007 – 2010)
- (2012) Giovanni Marzaro et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
- (2012) G. Siemeister et al. MOLECULAR CANCER THERAPEUTICS
- Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors
- (2012) M. McTigue et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EGFR Mutations and Lung Cancer
- (2011) Gilda da Cunha Santos et al. Annual Review of Pathology-Mechanisms of Disease
- A Force Field with Discrete Displaceable Waters and Desolvation Entropy for Hydrated Ligand Docking
- (2011) Stefano Forli et al. JOURNAL OF MEDICINAL CHEMISTRY
- Open Babel: An open chemical toolbox
- (2011) Noel M O'Boyle et al. Journal of Cheminformatics
- Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model
- (2010) Roque Diaz et al. BMC CANCER
- Synthesis of nitrogen bicyclic scaffolds: pyrimido[1,2-a]pyrimidine-2,6-diones
- (2010) Sylvain Grosjean et al. TETRAHEDRON
- Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
- (2009) D Yoshikawa et al. BRITISH JOURNAL OF CANCER
- Radiosensitization Effect of STI-571 on Pancreatic Cancer Cells In Vitro
- (2009) Hye Won Chung et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
- (2009) Garrett M. Morris et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc#
- (2009) Matthäus Getlik et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selectively Nonselective Kinase Inhibition: Striking the Right Balance
- (2009) Richard Morphy JOURNAL OF MEDICINAL CHEMISTRY
- The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound
- (2009) Simona Caporali et al. PHARMACOLOGICAL RESEARCH
- Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
- (2008) P MEDINA et al. CLINICAL THERAPEUTICS
- From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
- (2008) S. Giordano et al. CURRENT MEDICINAL CHEMISTRY
- The challenge of selecting protein kinase assays for lead discovery optimization
- (2008) Haiching Ma et al. Expert Opinion on Drug Discovery
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now